Download PDF
Digestive Disease Interventions 2019; 03(01): 003-013
DOI: 10.1055/s-0039-1679933
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Gastrointestinal Neuroendocrine Tumors: Clinical and Pathological Correlates

Sanjit Datta
1   Case Western Reserve University School of Medicine, Cleveland, Ohio
,
Annika Sinha
1   Case Western Reserve University School of Medicine, Cleveland, Ohio
,
Baljendra Kapoor
2   Department of Diagnostic Radiology, Cleveland Clinic Foundation, Cleveland, Ohio
› Author Affiliations
Further Information

Publication History

26 September 2018

21 January 2019

Publication Date:
07 March 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Gastrointestinal neuroendocrine tumors (GI-NETs), previously classified as carcinoid tumors, are rare cancers that arise from cells of the diffuse endocrine system of the gastrointestinal tract. These tumors most commonly arise from the bronchus, jejunoileum, or colon/rectum. They produce peptide products that can lead to identifiable clinical syndromes such as carcinoid syndrome, which is classically associated with diarrhea, flushing, and heart disease. The latest classifications of GI-NETs include pancreatic NETs, which can produce a wide range of pancreatic hormones leading to syndromes such as Zollinger–Ellison's syndrome. The prognosis for patients with GI-NETs varies widely depending on the size, location, and presence of metastatic disease, with 5-year survival rates ranging from 0 to 15% for poorly differentiated NETs and 10-year survival rates of up to 100% for patients with insulinomas smaller than 2 cm. A wide range of treatment modalities is commonly used to treat GI-NETs, including surgical and endoscopic resection, locoregional therapies, cytotoxic chemotherapy, and somatostatin receptor targeted therapy. The goal of this review is to detail the classification, epidemiology, clinical syndromes, diagnosis, and staging of these tumors and to provide an overview of management strategies.

Keywords

gastrointestinal neuroendocrine tumors - carcinoid - carcinoid syndrome - pancreatic neuroendocrine tumors - serotonin
 

  • References

  • 1 Yao JC, Hassan M, Phan A. , et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26 (18) 3063-3072
    CrossrefPubMedGoogle Scholar
  • 2 Kasper DL. In: Jameson L, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. , eds. Harrison's Principles of Internal Medicine. New York, NY: McGraw Hill; 2015
    Google Scholar
  • 3 Öberg K, Sundin A. Imaging of neuroendocrine tumors. Front Horm Res 2016; 45: 142-151
    PubMedGoogle Scholar
  • 4 Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015; 121 (04) 589-597
    CrossrefPubMedGoogle Scholar
  • 5 Grin A, Streutker CJ. Neuroendocrine tumors of the luminal gastrointestinal tract. Arch Pathol Lab Med 2015; 139 (06) 750-756
    CrossrefPubMedGoogle Scholar
  • 6 Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD. ; Knowledge NETwork. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer 2014; 21 (03) R153-R163
    PubMedGoogle Scholar
  • 7 Ter-Minassian M, Chan JA, Hooshmand SM. , et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer 2013; 20 (02) 187-196
    CrossrefPubMedGoogle Scholar
  • 8 Johnson PRV. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children. Semin Pediatr Surg 2014; 23 (02) 91-95
    CrossrefPubMedGoogle Scholar
  • 9 Pinato DJ, Tan TM, Toussi ST. , et al. An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. Br J Cancer 2014; 110 (01) 115-122
    CrossrefPubMedGoogle Scholar
  • 10 Kim HS, Lee HS, Nam KH, Choi J, Kim WH. p27 Loss is associated with poor prognosis in gastroenteropancreatic neuroendocrine tumors. Cancer Res Treat 2014; 46 (04) 383-392
    CrossrefPubMedGoogle Scholar
  • 11 Qian ZR, Ter-Minassian M, Chan JA. , et al. Prognostic significance of MTOR pathway component expression in neuroendocrine tumors. J Clin Oncol 2013; 31 (27) 3418-3425
    CrossrefPubMedGoogle Scholar
  • 12 Kerr SE, Schnabel CA, Sullivan PS. , et al. A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors. Mod Pathol 2014; 27 (01) 44-54
    CrossrefPubMedGoogle Scholar
  • 13 Francis JM, Kiezun A, Ramos AH. , et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet 2013; 45 (12) 1483-1486
    CrossrefPubMedGoogle Scholar
  • 14 Basuroy R, Srirajaskanthan R, Ramage JK. Neuroendocrine tumors. Gastroenterol Clin North Am 2016; 45 (03) 487-507
    CrossrefPubMedGoogle Scholar
  • 15 Kauffmann RM, Wang L, Phillips S, Idrees K, Merchant NB, Parikh AA. Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors. Ann Surg Oncol 2014; 21 (11) 3422-3428
    CrossrefPubMedGoogle Scholar
  • 16 Mapelli P, Aboagye EO, Stebbing J, Sharma R. Epigenetic changes in gastroenteropancreatic neuroendocrine tumours. Oncogene 2015; 34 (34) 4439-4447
    CrossrefPubMedGoogle Scholar
  • 17 Crona J, Skogseid B. GEP- NETS UPDATE: genetics of neuroendocrine tumors. Eur J Endocrinol 2016; 174 (06) R275-R290
    CrossrefPubMedGoogle Scholar
  • 18 Guilmette JM, Nosé V. Neoplasms of the neuroendocrine pancreas: an update in the classification, definition, and molecular genetic advances. Adv Anat Pathol 2019; 26 (01) 13-30
    CrossrefPubMedGoogle Scholar
  • 19 Rastogi V, Singh D, Mazza JJ, Parajuli D, Yale SH. Flushing disorders associated with gastrointestinal symptoms: part 1, neuroendocrine tumors, mast cell disorders and hyperbasophila. Clin Med Res 2018; 16 (1-2): 16-28
    CrossrefPubMedGoogle Scholar
  • 20 Grozinsky-Glasberg S, Grossman AB, Gross DJ. Carcinoid heart disease: from pathophysiology to treatment--‘something in the way it moves’. Neuroendocrinology 2015; 101 (04) 263-273
    CrossrefPubMedGoogle Scholar
  • 21 Palaniswamy C, Frishman WH, Aronow WS. Carcinoid heart disease. Cardiol Rev 2012; 20 (04) 167-176
    CrossrefPubMedGoogle Scholar
  • 22 Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart 2004; 90 (10) 1224-1228
    CrossrefPubMedGoogle Scholar
  • 23 Zandee WT, Kamp K, van Adrichem RCS, Feelders RA, de Herder WW. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. Eur J Endocrinol 2016; 175 (05) 361-366
    CrossrefPubMedGoogle Scholar
  • 24 Yang X, Yang Y, Li Z. , et al. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One 2015; 10 (04) e0124884
    CrossrefPubMedGoogle Scholar
  • 25 Öberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol 2010; 21 (Suppl. 07) vii72-vii80
    CrossrefPubMedGoogle Scholar
  • 26 Kim JY, Hong SM. Recent updates on neuroendocrine tumors from the gastrointestinal and pancreatobiliary tracts. Arch Pathol Lab Med 2016; 140 (05) 437-448
    CrossrefPubMedGoogle Scholar
  • 27 Chin JL, O'Toole D. Diagnosis and management of upper gastrointestinal neuroendocrine tumors. Clin Endosc 2017; 50 (06) 520-529
    CrossrefPubMedGoogle Scholar
  • 28 Feng ST, Luo Y, Chan T. , et al. CT evaluation of gastroenteric neuroendocrine tumors: relationship between CT features and the pathologic classification. AJR Am J Roentgenol 2014; 203 (03) W260-6
    PubMedGoogle Scholar
  • 29 de Herder WW. GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs). Eur J Endocrinol 2014; 170 (05) R173-R183
    CrossrefPubMedGoogle Scholar
  • 30 Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010; 51 (06) 875-882
    CrossrefPubMedGoogle Scholar
  • 31 Sadowski SM, Neychev V, Millo C. , et al. Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol 2016; 34 (06) 588-596
    PubMedGoogle Scholar
  • 32 Leung D, Schwartz L. Imaging of neuroendocrine tumors. Semin Oncol 2013; 40 (01) 109-119
    CrossrefPubMedGoogle Scholar
  • 33 Sato Y, Hashimoto S, Mizuno K, Takeuchi M, Terai S. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol 2016; 22 (30) 6817-6828
    CrossrefPubMedGoogle Scholar
  • 34 Basturk O, Yang Z, Tang LH. , et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015; 39 (05) 683-690
    CrossrefPubMedGoogle Scholar
  • 35 Chagpar R, Chiang YJ, Xing Y. , et al. Neuroendocrine tumors of the colon and rectum: prognostic relevance and comparative performance of current staging systems. Ann Surg Oncol 2013; 20 (04) 1170-1178
    CrossrefPubMedGoogle Scholar
  • 36 Landry CS, Brock G, Scoggins CR, McMasters KM, Martin II RCG. A proposed staging system for small bowel carcinoid tumors based on an analysis of 6,380 patients. Am J Surg 2008; 196 (06) 896-903 , discussion 903
    CrossrefPubMedGoogle Scholar
  • 37 National Comprehensive Cancer Network. Guidelines: Neuroendocrine and Adrenal Tumors. Plymouth Meeting, PA: NCCN; 2018
    PubMedGoogle Scholar
  • 38 McDermott S, O'Neill AC, Skehan SJ. Staging of gastroenteropancreatic neuroendocrine tumors: how we do it based on an evidence-based approach. Clin Imaging 2013; 37 (02) 194-200
    CrossrefPubMedGoogle Scholar
  • 39 Gleeson FC, Levy MJ, Dozois EJ, Larson DW, Wong Kee Song LM, Boardman LA. Endoscopically identified well-differentiated rectal carcinoid tumors: impact of tumor size on the natural history and outcomes. Gastrointest Endosc 2014; 80 (01) 144-151
    CrossrefPubMedGoogle Scholar
  • 40 Yao JC, Fazio N, Singh S. , et al; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387 (10022): 968-977
    CrossrefPubMedGoogle Scholar
  • 41 Kleiman DA, Finnerty B, Beninato T. , et al. Features associated with metastases among well-differentiated neuroendocrine (carcinoid) tumors of the appendix: the significance of small vessel invasion in addition to size. Dis Colon Rectum 2015; 58 (12) 1137-1143
    CrossrefPubMedGoogle Scholar
  • 42 Khan MS, Kirkwood A, Tsigani T. , et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol 2013; 31 (03) 365-372
    PubMedGoogle Scholar
  • 43 Oberg K, Modlin IM, De Herder W. , et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol 2015; 16 (09) e435-e446
    CrossrefPubMedGoogle Scholar
  • 44 Reubi J. Schonbrunn, A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci 2014; 34: 1-27
    PubMedGoogle Scholar
  • 45 Walenkamp A, Crespo G, Fierro Maya F. , et al. Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment. Endocr Relat Cancer 2014; 21 (06) R445-R460
    CrossrefPubMedGoogle Scholar
  • 46 Rinke A, Wittenberg M, Schade-Brittinger C. , et al; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology 2017; 104 (01) 26-32
    CrossrefPubMedGoogle Scholar
  • 47 Wolin EM, Jarzab B, Eriksson B. , et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther 2015; 9: 5075-5086
    PubMedGoogle Scholar
  • 48 Oberg K. Interferons in the management of neuroendocrine tumors and their possible mechanism of action. Yale J Biol Med 1992; 65 (05) 519-529 , discussion 531–536
    PubMedGoogle Scholar
  • 49 Kulke MH. Neuroendocrine tumors: is there a standard treatment?. Gastrointest Cancer Res 2008; 2 (03) 152-153
    PubMedGoogle Scholar
  • 50 Sorbye H, Welin S, Langer SW. , et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013; 24 (01) 152-160
    CrossrefPubMedGoogle Scholar
  • 51 Xu C, Zhang H. Somatostatin receptor based imaging and radionuclide therapy. BioMed Res Int 2015; 2015: 917968
    PubMedGoogle Scholar
  • 52 Strosberg J, El-Haddad G, Wolin E. , et al; NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
    CrossrefPubMedGoogle Scholar
  • 53 Jeon JH, Cheung DY, Lee SJ. , et al. Endoscopic resection yields reliable outcomes for small rectal neuroendocrine tumors. Dig Endosc 2014; 26 (04) 556-563
    CrossrefPubMedGoogle Scholar
  • 54 Mayo SC, de Jong MC, Pulitano C. , et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010; 17 (12) 3129-3136
    CrossrefPubMedGoogle Scholar
  • 55 Saeed A, Buell JF, Kandil E. Surgical treatment of liver metastases in patients with neuroendocrine tumors. Ann Transl Med 2013; 1 (01) 6
    PubMedGoogle Scholar
  • 56 Lesurtel M, Nagorney DM, Mazzaferro V, Jensen RT, Poston GJ. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford) 2015; 17 (01) 17-22
    CrossrefPubMedGoogle Scholar
  • 57 Osborne DA, Zervos EE, Strosberg J. , et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13 (04) 572-581
    CrossrefPubMedGoogle Scholar
  • 58 Gupta S. Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases. Semin Intervent Radiol 2013; 30 (01) 28-38
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007; 142 (01) 10-19
    CrossrefPubMedGoogle Scholar
  • 60 Rossi RE, Burroughs AK, Caplin ME. Liver transplantation for unresectable neuroendocrine tumor liver metastases. Ann Surg Oncol 2014; 21 (07) 2398-2405
    CrossrefPubMedGoogle Scholar
  • 61 Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002; 32 (02) 123-132
    CrossrefPubMedGoogle Scholar
  • 62 Delpassand ES, Sims-Mourtada J, Saso H. , et al. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm 2008; 23 (03) 292-300
    CrossrefPubMedGoogle Scholar
  • 63 Forrer F, Waldherr C, Maecke HR, Mueller-Brand J. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res 2006; 26 (1B): 703-707
    PubMedGoogle Scholar
  • 64 Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12 (07) 941-945
    CrossrefPubMedGoogle Scholar
  • 65 Kwekkeboom DJ1, de Herder WW, Kam BL. , et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26 (13) 2124-2130
    CrossrefPubMedGoogle Scholar
  • 66 Sansovini M, Severi S, Ambrosetti A. , et al. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology 2013; 97 (04) 347-354
    CrossrefPubMedGoogle Scholar
  • 67 Seregni E, Maccauro M, Chiesa C. , et al. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging 2014; 41 (02) 223-230
    CrossrefPubMedGoogle Scholar
  • 68 Kratochwil C, Giesel FL, Bruchertseifer F. , et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging 2014; 41 (11) 2106-2119
    CrossrefPubMedGoogle Scholar